2013-01-21 15:28:09 - New Pharmaceuticals market report from GlobalData: "ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis"

GlobalData has released its new PharmaPoint Drug Evaluation report, "ASP7374 (Seasonal Influenza Vaccines) Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers

that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.


Full Report Details at
- www.fastmr.com/prod/529889_asp7374_seasonal_influenza_vaccines_f ..


ASP7374 (UMN-0502) is a recombinant protein-based vaccine manufactured using a baculovirus expression vector system. UMN Pharma obtained the rights to vaccine development for FluBlok in various Asian countries, including Japan, China, and South Korea, from Protein Sciences Corporation, and subsequently set about to develop UMN-0502 as its own seasonal influenza vaccine. Since the deal, UMN Pharma has licensed the product to Astellas Pharma as part of a development collaboration between the companies.

Scope

* Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on ASP7374 including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for ASP7374 from 2012 to 2022.
* Sales information covered for Japan

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition n by understanding the changing competitive landscape for seasonal influenza
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of ASP7374 performance
* Obtain sales forecast for ASP7374 from 2012 to 2022 in Japan.

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Higher Level of Patient Awareness
6.2.2 Increased Efficacy in the Elderly and Young Children (<2 years old)
6.2.3 Improved Vaccine Side-Effect Profiles
6.2.4 More Efficient Vaccine Manufacturing Process
6.2.5 More Cost-Effective Vaccines
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Expanded Breadth of Protection Against Viral Strains
6.4.2 Increased Duration of Protection
6.4.3 T-cell Involvement
7 Pipeline Assessment
7.1 Overview
7.2 Promising Vaccines in Clinical Development
7.2.1 ASP7374 (UMN-0502)
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 Forecasting Methodology
8.4.1 Vaccine Coverage
8.4.2 Vaccines Included
8.4.3 Influenza Vaccine Tender System Assumptions
8.4.4 General Pricing Assumptions
8.4.5 Pricing of Pipeline Agents
8.5 Physicians and Specialists Included in this Study
8.6 Primary Research - Prescriber Survey
8.7 About the Authors
8.7.1 Authors
8.7.2 Global Head of Healthcare
8.8 About GlobalData
8.9 Contact Us
8.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012
Table 5: Leading Influenza Vaccines, 2012
Table 6: Overall Unmet Needs - Current Level of Attainment
Table 7: Clinical Unmet Needs - Gap Analysis, 2012
Table 8: Seasonal Influenza Vaccines - Phase Pipeline, 2012
Table 9: Product Profile - ASP7374
Table 10: ASP7374 SWOT Analysis, 2012
Table 11: Global Sales Forecasts ($m) for ASP7374 (UMN-0502), 2012-2022
Table 12: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: Influenza Virus Structure
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Seasonal Influenza, 2012-2022

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.